Australia vs Saudi Arabia: The number of people with susceptibility test result for rifampicin
Australia
597
in 2021
Saudi Arabia
591
in 2021
Australia rank
76th
Saudi Arabia rank
77th
The number of people with susceptibility test result for rifampicin over time
- Australia
- Saudi Arabia
How they compare
Australia currently reports 597 against 591 in Saudi Arabia, a difference of 6.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Saudi Arabia ahead.
Australia ranks 76th and Saudi Arabia ranks 77th of 155 countries.
Across the 2 decades both report, Australia averaged higher in 1 and Saudi Arabia in 1.
Head to head by decade
| Decade | Australia | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 702.67 | 1,131 | 428.33 | Saudi Arabia |
| 2020s | 666 | 590.5 | 75.5 | Australia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Australia or Saudi Arabia?
- Australia, at 597 against 591 in Saudi Arabia as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Australia and Saudi Arabia?
- 6, with Australia ahead.
- How many years of comparable data are there for Australia and Saudi Arabia?
- 5 years are reported by both, from 2017 to 2021.
- How do Australia and Saudi Arabia rank globally for the number of people with susceptibility test result for rifampicin?
- Australia ranks 76th and Saudi Arabia ranks 77th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.